Among CCR5 blocking antibodies, a humanized anti-CCR5 Leronlimab in combination with Carboplatin is currently under investigation in phase 1b/2 clinical trial ClinicalTrials.gov identifier: NCT03838367) for patients with CCR5+ metastatic triple negative breast cancer (159). The gene discussed is CCR5; the disease is triple-negative breast carcinoma.